Skip to main content
    N

    Nautilus Biotechnology Inc (NAUT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.16
    +0.00 (+0.00%)

    Market Cap: $260.87M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(19/22)
    Avg Surprise
    -9.03%
    Streak
    19 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.15 - $-0.14
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.15+4.5%
    60d ago$-0.15+4.5%
    30d ago$-0.15+4.5%
    7d ago$-0.14+1.2%
    Current$-0.14
    Revenue Consensus
    $206250
    Range$200000 - $225000
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.10 - $-0.05
    4 analysts
    Revenue Consensus
    $330000
    Range$293750 - $438750
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Jul 28
    		$-0.11$-0.14+21.43%Beat+8.3%
    Mar 26
    Reported Apr 28
    		$-0.12$-0.14+14.29%Beat+7.7%
    Dec 25
    Reported Feb 26
    		$-0.11$-0.15+29.03%Beat+21.4%
    Sep 25
    Reported Oct 27
    		$-0.11$-0.15+26.67%Beat+15.4%
    Jun 25
    Reported Jul 31
    		$-0.12$-0.14+14.29%Beat+14.3%
    Mar 25
    Reported Apr 29
    		$-0.13$-0.14+7.14%Beat+13.3%
    Dec 24
    Reported Feb 26
    		$-0.14$-0.15+6.67%Beat+0.0%
    Sep 24
    Reported Oct 29
    		$-0.13$-0.17+23.53%Beat+0.0%
    Jun 24
    Reported Jul 30
    		$-0.14$-0.16+12.50%Beat-7.7%
    Mar 24
    Reported Apr 30
    		$-0.15$-0.16+6.25%Beat-25.0%
    Dec 23
    Reported Feb 28
    		$-0.14$-0.14+0.00%Beat-27.3%
    Sep 23
    Reported Oct 31
    		$-0.13$-0.16+18.75%Beat-18.2%
    Jun 23
    Reported Aug 2
    		$-0.13$-0.16+18.75%Beat-8.3%
    Mar 23
    Reported May 2
    		$-0.12$-0.17+29.41%Beat+7.7%
    Dec 22
    Reported Feb 23
    		$-0.11$-0.15+26.67%Beat+15.4%
    Sep 22
    Reported Nov 1
    		$-0.11$-0.15+26.67%Beat+8.3%
    Jun 22
    Reported Aug 2
    		$-0.12$-0.17+29.41%Beat+36.8%
    Mar 22
    Reported May 3
    		$-0.13$-0.16+18.75%Beat+62.9%
    Dec 21
    Reported Feb 24
    		$-0.13$-0.13+0.00%Beat-550.0%
    Sep 21
    Reported Nov 2
    		$-0.12$-0.10-20.00%Miss-1100.0%
    Jun 21
    Reported Aug 10
    		$-0.19$-0.07-171.43%Miss-
    Mar 21
    Reported Jun 10
    		$-0.35$-0.08-337.50%Miss-
    Dec 20
    Reported Mar 30
    		$-0.02N/AN/ABeat-
    Sep 20
    Reported Nov 13
    		$-0.01N/AN/ABeat-
    Jun 20
    Reported Sep 18
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.80EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-8296.00%
    ROE-36.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.14xQuick Ratio10.14x
    Trading Statistics
    Beta0.73Avg Volume8.43M
    52-Week High$4.3152-Week Low$0.84

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.02
    SMA 20$1.57
    SMA 50$1.18
    SMA 200$2.08
    EMA 10$1.96
    EMA 20$1.70
    EMA 50$1.46
    EMA 200$1.72

    MACD

    Line: 0.30Signal: 0.24Hist: 0.06

    ADX

    ADX: 49.6+DI: 31.7-DI: 7.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$1.87

    Bollinger Bands

    Upper Band$2.57
    Lower Band$0.58
    %B Position12613%(Upper)
    Band Width0.80

    RSI (14-Day)

    Neutral
    69.2

    Momentum Oscillators

    Stoch %K76.8
    Stoch %D77.7
    Williams %R-21.2
    ROC (10d)37.6%
    Momentum0.59
    CCI (20d)77.0
    MFI (14d)71.0

    Volatility Measures

    ATR (14d)$0.28(13.0%)
    StdDev (20d)0.50
    Hist Vol163.2%(High)

    Volume Flow

    VWAP$2.08
    OBV19.9M
    AD Line-11.6M
    CMF (20d)0.067

    Volume Metrics

    Avg Vol (20d)9.2M
    Vol Ratio0.9x
    VWMA (20d)$1.82

    Pivot Points

    R3$2.54
    R2$2.37
    R1$2.26
    Pivot Point$2.09
    S1$1.98
    S2$1.81
    S3$1.70

    Advanced Oscillators

    TSI40.50
    Ultimate Osc58.7
    KST1013.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$190,000$0$0$0$0$0$9.60M$0$0$0$8.21M$0
    Cost of Revenue$15,000$0$1.59M$1.62M$0$0$6.35M$0$0$0$1.59M$0
    Gross Profit$175,000$0$-1,588,000$-1,619,000$0$0$-6,353,000$0$0$0$-1,590,000$0
    Operating Expenses$15.94M$16.12M$13.84M$15.47M$17.10M$18.84M$19.98M$19.10M$20.79M$21.61M$20.00M$19.07M
    R&D$9.61M$9.71M$10.92M$9.61M$10.39M$11.54M$12.82M$12.29M$12.44M$12.93M$12.47M$12.00M
    SG&A$6.33M$6.42M$5.85M$5.87M$6.70M$7.31M$7.16M$6.81M$8.35M$8.68M$7.54M$7.08M
    Operating Income$-15,763,000$-16,124,000$-15,424,000$-15,472,000$-17,097,000$-18,844,000$-19,980,000$-19,100,000$-20,789,000$-21,607,000$-20,001,000$-19,075,000
    Interest Income$1.31M$1.44M$1.65M$1.90M$2.08M$2.23M$2.43M$2.67M$2.80M$2.88M$3.03M$3.20M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-14,469,000$-14,697,000$-13,781,000$-13,574,000$-15,033,000$-16,613,000$-17,594,000$-16,446,000$-18,010,000$-18,730,000$-17,024,000$-15,878,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-14,469,000$-14,697,000$-13,781,000$-13,574,000$-15,033,000$-16,613,000$-17,594,000$-16,446,000$-18,010,000$-18,730,000$-17,024,000$-15,878,000
    EBITDA$-14,480,000$-14,731,000$-12,193,000$-11,955,000$-15,919,000$-17,760,000$-18,971,000$-18,231,000$-22,073,000$-20,767,000$-19,086,000$-18,220,000
    EBIT$-15,776,000$-16,139,000$-13,781,000$-13,574,000$-17,113,000$-18,844,000$-19,980,000$-19,120,000$-20,808,000$-21,607,000$-20,057,000$-19,075,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NAUT

    News

    Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026

    Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will report its third-quarter 2026 financial results before market open on Tuesday, October 27...

    Yahoo Finance UK•10/15/26•Neutral

    Nautilus Biotechnology to Report Third Quarter 2026 Financial Results on October 27

    Nautilus Biotechnology will release its Q3 2026 financial results on October 27, 2026, before market open, followed by a management webcast at 5:30 a.m. Pacific Time. The company, focused on protein analysis technology...

    Quiver Quantitative•10/15/26•Neutral

    Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026

    Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will report its third quarter 2026 financial results before market open on Tuesday, October 27...

    GlobeNewswire•10/15/26•Neutral

    NAUT Stock Climbs As Bullish Coverage Backs Voyager Platform

    Nautilus Biotechnology Inc. (NAUT) stock climbed 12.76% after receiving bullish coverage from Roth Capital and Leerink, both initiating Buy/Outperform ratings with price targets of $3.50 and $4...

    Timothy Sykes•10/2/26•Neutral

    NAUT Stock Climbs As Wall Street Backs Voyager Platform

    Nautilus Biotechnology Inc. (NAUT) stock has climbed by 12.74% due to bullish sentiment surrounding its AI-powered Voyager proteomics platform. Wall Street firms Roth Capital and Leerink Partners initiated coverage...

    StocksToTrade•10/2/26•Bullish

    NAUT Valuation and Fair Value

    P/E
    -4.8x
    P/B
    2.1x
    See GNG's fair value

    NAUT Profitability: Margins, ROIC and FCF

    Operating margin
    -8296.0%
    Net margin
    0.0%
    ROE
    -36.2%

    NAUT Competitors

    CompanyTicker
    Treace Medical Concepts IncTMCI
    Standard Biotools IncLAB
    InfuSystems Holdings IncINFU
    Palisade Bio IncPALI
    Anika Therapeutics IncANIK
    Prelude Therapeutics IncPRLD
    Surrozen IncSRZN
    EyePoint, IncEYPT

    Sector: Healthcare

    NAUT Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    NAUT Bull Case vs Bear Case

    Bull case

    • NAUT beat EPS estimates in 100.0% of its last 8 reported quarters.

    NAUT Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    17.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About NAUT

    Does NAUT pay dividends?

    Nautilus Biotechnology Inc (NAUT) does not currently pay a regular dividend.

    What is NAUT's market cap?

    Nautilus Biotechnology Inc (NAUT) has a market capitalization of $260.87M with a current stock price of $2.16.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In